Navigation Links
MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
Date:10/30/2008

GERMANTOWN, Md., Oct. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, is scheduled to announce its financial results for the third quarter of 2008 on Thursday, Nov. 13, 2008, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review the Company's third quarter financial results.

To listen live to the call, dial 1-800-813-8504 or 1-706-643-7752. A replay of the call will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Nov. 20, 2008. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID # 71538195.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, http://www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Dec. 12, 2008.

About Middlebrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in pulses are killed more efficiently than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the KEFLEX(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit http://www.middlebrookpharma.com.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
2. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
3. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
6. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
7. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
8. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
10. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
11. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... SuperCloset is ... all too well the day to day issues, struggles and obstacles veterans’ need to ... Helping Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults ... that bariatric surgery has received increased attention in recent years, as an article ... comes to weight loss, most people are familiar with the basic requirements of maintaining ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: